Larotaxel

Drug Profile

Larotaxel

Alternative Names: 109,881; PNU 100940; RPR 109881A; RPR109881; Taxoid 109881; XRP9881

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 31 Dec 2010 Development discontinued for Bladder cancer (first-line therapy, metastatic disease) during 2010 in Argentina (IV)
  • 31 Dec 2010 Development discontinued for Bladder cancer (first-line therapy, metastatic disease) during 2010 in Australia (IV)
  • 31 Dec 2010 Development discontinued for Bladder cancer (first-line therapy, metastatic disease) during 2010 in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top